Liver transplantation and transthyretin amyloidosis

Research output: Contribution to journalReview articlepeer-review

59 Scopus citations


Liver transplantation as a specific treatment of transthyretin amyloidosis was first performed in 1990. The rationale for this treatment was that removal of the source (liver) of the amyloid precursor protein (mutated transthyretin) would stop progression of the disease. Indeed, after orthotopic liver transplantation (OLT), mutant transthyretin (TTR) is rapidly cleared from circulation. In the last 20 years, >2000 familial amyloidotic polyneuropathy (FAP) patients have received liver transplants. For these patients, prospective monitoring has shown prolongation of life compared with FAP patients who have not undergone liver transplantation. The most favorable results have been for FAP patients with the Val30Met TTR mutation. Less favorable results have been seen for patients with other TTR mutations where progression of amyloid tissue deposition has been documented as the result of amyloid fibril formation from normal (wild-type) TTR. Although it is obvious that OLT has benefited many FAP patients, there remains a need for further therapies.

Original languageEnglish (US)
Pages (from-to)157-162
Number of pages6
JournalMuscle and Nerve
Issue number2
StatePublished - Feb 2013


  • Amyloidosis
  • Familial amyloidotic polyneuropathy
  • FAP
  • Liver transplant
  • Transthyretin
  • TTR

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Fingerprint Dive into the research topics of 'Liver transplantation and transthyretin amyloidosis'. Together they form a unique fingerprint.

Cite this